What happens when the biopharmaceutical industry tries to force living, hyper-perishable cell therapies into a legacy supply chain built for shelf-stable small molecules?

The entire system breaks down.

In this episode of Out of the Lab, host Nico sits down with Hedley Rees, Managing Director of PharmaFlow and a 40-year biopharma supply chain veteran, to pull back the curtain on why advanced therapies are hitting an operational dead end. Hedley details the immense logistical dangers of circular, "vein-to-vein" CAR-T workflows, the vulnerabilities left unaddressed by major wholesale distributors, and why the current industry model is built entirely on a structural paradox.

We pull apart:

• The Evolution of Tech Friction: Why modern manufacturing architectures were never truly re-engineered to survive deep cryogenic and cold chain realities.
  

• The 99% Attrition Trap: How archaic patent laws incentivize companies to claim molecules before establishing repeatable, scalable manufacturing processes.
  

• Post-Contractual Moral Hazard: The commercial reality check of what happens when private-equity-backed CDMOs hold all the leverage, leaving asset owners to face regulatory scrutiny alone.
  

• Back to the Future: Leveraging the collaboration model of Penicillin to integrate clinicians and engineers directly back into early-stage drug development.

Timestamps & Chapters:

• 00:00 – Introduction: Discussing operational complexity in cell and gene therapy.

• 01:44 – Alka-Seltzer vs. Monoclonal Antibodies: The failure to re-engineer legacy logistics.

• 03:34 – CAR-T Realities: Demystifying the highly volatile, circular "vein-to-vein" supply chain.

• 07:07 – Handover Hazards: Real-time tracking, temperature excursions, and runway failures.

• 13:26 – The Penicillin Blueprint: Why the earliest breakthrough required process over molecule.

• 19:39 – Changing the Rules: Redesigning patent law to solve structural asset attrition.

• 29:46 – The CDMO Leverage Trap: Navigating post-contractual moral hazard on the floor.

• 46:15 – Shared Risk Alliances: The future of integrated manufacturing capability.

What happens when a life-saving gene therapy is developed for a patient population of only 30 people? The traditional pharmaceutical business model completely breaks down.

In this episode of Out of the Lab, host Nico sits down with Craig Martin, CEO and Founder of the Orphan Therapeutics Accelerator, to dissect the radical operational and financial shifts required to bring advanced therapies to ultra-rare disease communities. Craig shares how his non-profit accelerator is rewriting the playbook, from rescuing and "ring-fencing" shelved pharma assets to establishing a shared clinical development network (Orphan ClinDevNet) that spreads infrastructure costs across multiple therapies.

They dive deep into the gritty operational realities of advanced therapies: the staggering financial burdens placed on caregivers, the ethical dilemmas of placebo-controlled arms in pediatric trials, and why a reimbursement system built for chronic, recurring pills fundamentally fails a one-time cure.

Discussion Points:

• The Shared Infrastructure Fix: Discover how the Orphan ClinDevNet partners with specialized CDMOs and CROs to build a repeatable framework, avoiding the need to reinvent the manufacturing wheel for every single ultra-rare indication.

• The Non-Profit Win-Win for IP: Learn how biotech companies can safely out-license or ring-fence shelved rare disease assets to a non-profit accelerator without losing the commercial upside for larger, subsequent indications.

• The $1 Trillion Problem: Why leaving rare diseases untreated costs the US healthcare system over $1 trillion annually, and why a high one-time cure price tag is actually a collective macroeconomic win.

• 00:00 - Introduction & The Rare Disease Market Failure

• 02:14 - Scaling Efficiencies: What is the Orphan ClinDevNet?

• 05:30 - Rescuing Shelved IP via a Non-Profit Accelerator Model

• 08:45 - The Operational and Regulatory Bottlenecks (CMC Batches & Placebos)

• 12:15 - The Real Cost of Caregiving: Travel, Lodging, and OIG Regulations

• 15:40 - Why Our Reimbursement System Fails One-Time Cures

• 19:10 - Platform Approvals & The Future of "Plausible Mechanism" Access

"Cell and gene therapy developers are contending with the same problems the early pioneers of lean production contended with. Specifically, a frugal environment with scarce resources."

 — Andrew, ScaleReady. 

In this episode of Out of the Lab, we sit down with Andrew from ScaleReady to discuss the operational parallels between historical manufacturing revolutions and the current challenges in cell and gene therapy.

We explore how "lean" manufacturing principles originally developed by Toyota for resource-scarce environments can be applied to modern cell therapy development to solve the industry’s most pressing operational hurdles. Andrew shares insights into why adopting these established frameworks can help developers streamline processes, reduce waste, and overcome the "frugal" environment many pioneers currently face.

Topics covered:

• The relevance of the Toyota Way in modern biotech.

• Navigating resource scarcity in cell therapy manufacturing.

• Why lean methodologies resonate with cell and gene therapy pioneers.

  
  

  Timestamps & Key Takeaways:

• 00:00 – 03:00 | Introduction: Setting the stage for the operational challenges in cell and gene therapy.

• 03:00 – 08:30 | Defining the "Frugal" Environment: A discussion on the current macro-economic pressures facing developers and why efficiency is no longer optional.

• 08:30 – 15:45 | The Lean Parallel: Exploring the historical origins of lean production (Toyota Way) and why those original, resource-constrained conditions mirror the current challenges in cell therapy development.

• 15:45 – 22:10 | Operational Hurdles: Why the "widget" approach in manufacturing is often misunderstood or misapplied in early-stage biotech.

• 22:10 – 30:00 | Scarcity as a Catalyst: How resource scarcity can actually force better innovation and rigorous process design.

• 30:00 – 37:30 | Lean Discipleship: Andrew shares his journey into becoming a "lean disciple" and the value of reading foundational texts like The Toyota Way to solve modern biotech bottlenecks.

• 37:30 – 42:00 | Closing Thoughts: Final advice for cell and gene therapy developers looking to align their internal operations with the high stakes of commercialization.

How do you scale a supply chain when an entire manufacturing run is for one patient, and the starting material is inside them?

In this episode of Out of the Lab, we dive deep into the messy, complex, and high-stakes world of cell and gene therapy (CGT) logistics. Joining us again is Tatyana Matveeva, Director of cGMP Operations at Harvard Medical School and Massachusetts General Hospital, to break down the nuanced complexities and differences of supply chain risks in cell/gene therapies, and biologics.

Tatyana challenges the industry's habit of oversimplifying supply chain security down to just "having duplicates," and introduces a much-needed framework: Risk Intelligence.

From the extreme environmental volatility of live biologics to the profound operational shift required for autologous therapies, this conversation is a masterclass in modern biotech operations.

Key Takeaways from This Episode:

• Beyond "Plan B": Why true supply chain security requires rigorous, realistic stress-testing across an asset's entire life cycle, not just a list of backup suppliers.

• The Biologics Paradox: How the extreme sensitivity of advanced therapies to light, temperature, and mechanical stress shifts patient access from a clinical question to a logistical one.

• Process Uniformity vs. Mastery: A deep dive into the autologous space, where the patient is the starting material, making variability inevitable and "process mastery" non-negotiable.

• 00:00 – Introduction: The operational challenges of personalized medicine.

• 01:59 – Moving beyond "secure duplicates" in clinical trials.

• 07:20 – The volatility of biologics and its direct impact on patient access.

• 13:04 – Implementing a "risk-intelligent" approach to prevent asset extinction.

• 27:18 – Autologous vs. Allogeneic: Why uniform processes can still be flawed.

• 33:00 – Centralized care: The reality of patients as part of the supply chain.

• 40:10 – International regulations, GMP harmonization, and public health impact.

In this episode of Out of the Lab, we tackle the intersection of cutting-edge technology and strict biopharma regulation. We are joined by Jose Caraballo-Oramas (Founder & Principal Advisor, JCO Global Advisory LLC, former Vice President of Global Compliance, Quality Systems & Quality Engineering at Kite Pharma), to discuss the real-world boundaries of AI in GxP environments.

Jose breaks down a crucial reality check for life science innovators: while AI can analyze millions of data points, it cannot legally or operationally hold accountability. He shares insight into why critical decision-making nodes, like batch product release must remain strictly human-driven.

In this episode, we cover:

• The Performance Review Rule: Why the FDA inspects people, not algorithms.

• Peripheral vs. Core GMP: How to safely deploy AI in support workflows like maintenance schedules and document sorting to build regulatory trust.

• Computer Software Assurance (CSA): Utilizing modern FDA guidelines to replace redundant "checkbox" testing with risk-based critical thinking.

  Show notes:

• 00:00 — Introduction & Welcome

• 00:31 — The FDA’s "Hot-Off-the-Press" AI Warning Letter

• 01:45 — The "Cringiest" AI Regulatory Citation

• 04:58 — The Golden Rule of GMP: You Can't Delegate Accountability

• 06:01 — AI as an Operational Aid vs. Decision Maker

• 07:25 — Hospital Procurement & The 2% Error Margin

• 10:24 — Validated Applications: Inspection & Automation

• 11:58 — Unpacking the FDA's Computer Software Assurance (CSA) Guidelines

• 12:57 — Shifting from Checkbox Validation to Critical Thinking

• 14:26 — The True Application of CSA

• 15:58 — Timeline Compression: The Strategic Benefits for Biotech

• 17:56 — Debunking the Myth: CSA is Not "Less Documentation"

• 18:44 — The Bedside Impact: When Does Validation Help the Patient?

• 22:03 — Episode Outro & Wrap-Up

In this episode of the Out of the Lab Podcast, we sit down with Dr. Rishi Chavan from the Children's Hospital of Orange County. As a pediatric oncologist specializing in stem cell transplants, Dr. Chavan provides a unique perspective on bridging the gap between clinical practice and the research of cell and gene therapies. We dive into the true purpose of standard operating procedures (SOPs) and how rethinking documentation can transform medical outcomes.

In this episode, we cover:

• The current hurdles for access to cell and gene therapy, including financial toxicity and regulatory burdens.

• Why accreditations and quality control programs are essential safety guardrails for high-risk treatments.

• The "Chef vs. Cook" analogy for standardizing and transferring clinical protocols.

• The mindset shift from treating complications to proactively anticipating and preventing them.

• How to design "Google Maps" style documentation that allows users to zoom in for details and zoom out for the big picture.

Timestamps / Chapters:

• 00:00 - Introduction to Dr. Rishi Chavan and his background at the Children's Hospital of Orange County.

• 01:44 - Discussing the financial, regulatory, and manufacturing challenges restricting access to cell and gene therapy.

• 07:33 - Exploring decentralized remote patient monitoring and the hub-and-spoke model.

• 09:18 - Why accreditations aren't just red tape, but necessary guardrails to protect patients.

• 18:28 - The Chef and the Cook: How creative R&D translates into scalable lab manuals.

• 33:10 - Why elite doctors and scientists use protocols to anticipate complications before they happen.

  35:52 - The Google Maps analogy: Creating effective, telescoping SOPs without overwhelming the reader.

What happens after a patient survives a groundbreaking clinical trial?

In this episode of Out of the Lab, host Nicholas Crudele sits down with Betsy Larrabee, a parent and patient advocate, to discuss the realities of pediatric CAR T-cell therapy. While cell therapy offers incredible curative potential, Betsy reveals the massive gaps in post-treatment care and the illusion of a cancer "finish line".

Drawing from her family's journey with her son, Bo , Betsy breaks down the systemic socioeconomic barriers that keep life-saving treatments out of reach for most families.

Key Takeaways:

• The profound lack of medical infrastructure for managing long-term immunological side effects, such as subclinical IgA, after successful trial treatments.

• Why clinical trial designs urgently need to incorporate dedicated follow-on care teams.

• The staggering financial and logistical burdens of centralized care, including spending nearly six figures, maintaining two households, and traveling across the country 22 times for follow-ups.

• The harsh reality that 80% of patients who could benefit from CAR T-cell therapy lack the socioeconomic privilege or geographic access to receive it.

In this episode of Out of the Lab, host Nico Crudele is joined by Adrienne Mendoza from BBG to unpack the massive operational challenges holding back patient access in cell and gene therapy.

We discuss why the physical science isn't the primary bottleneck, but rather the translation of that science to the community through three pillars: place, knowledge, and affordability. Adrienne shares how mobile apheresis units are decentralizing the highly technical cell collection process, drastically reducing the financial and logistical travel burdens placed on patients and their caregivers.

We also take a hard look at the data side of the supply chain. We discuss why relying on paper records introduces dangerous manual errors into time-sensitive batches, and how these delays can literally cost patients their lives when they don't have weeks to wait. Finally, we break down why true electronic batch records with API integration are essential, and why "paper on glass" solutions fall short.

Timestamps & Key Topics

00:00:00 – The Barriers to Access00:01:51 – Geography as a Hurdle00:03:11 – Mobile Leukapheresis: Reaching the Patient

00:06:19 – The Economics of Community Access00:09:16 – The "Hub and Spoke" Model00:13:35 – The Power of Electronic Batch Records (EBR)00:18:20 – Refining Manufacturing with Data00:22:17 – The Future: Integration and Visibility

In this episode of the Out of the Lab Podcast, we sit down with Tatyana Matveeva, head of cGMP operations at Harvard, to discuss the documentation challenges in cell and gene therapy tech transfer.

We dive deep into the cultural divide between GMP operations and research environments.

Tatyana explains why therapies developed over decades in an academic setting struggle to transition into clinical manufacturing.

We cover the massive financial and time costs associated with deviations, why process validation in a new facility is mandatory, and why "visceral" lab knowledge must be translated into concrete, GMP-grade documentation to protect patients and ensure regulatory approval.

Key Topics Discussed:

• The fundamental differences in documentation requirements between research and GMP.

• Why successful research runs do not guarantee a seamless tech transfer.

• The exponential time and financial costs of CAPA investigations and scrapped batches.

• Why "visceral" understanding of a process isn't enough to train operators or run subsequent batches.

Show Notes:

00:00:37 - The Cultural Divide Between Research and GMP

• Discussing how therapies originating from decades of lab work must transition into a GMP environment.

• Scientists often face challenges adapting to the full scope of GMP compliance and documentation.

00:07:45 - The Purpose of Documentation: Research vs. GMP

• Research documentation focuses primarily on reproducibility.

• GMP documentation requires strict traceability—including exact dates, times, and personnel flow—to ensure patient safety and product integrity.

00:14:15 - The Exponential Cost of Deviations

• Unlike in research, mistakes in clinical manufacturing can cause operations to stop completely and require materials to be scrapped.

• A single week of delay can easily snowball into three to five weeks of lost time for the patient.

00:17:06 - "Visceral Doesn't Count" in Manufacturing

• While scientists may have a "visceral" understanding of their processes, GMP requires explicit, concrete articulation for training and batch replication.

00:18:00 - The Illusion of Seamless Tech Transfers

• Replicating a process successfully in a research setting does not guarantee a successful tech transfer if the team lacks GMP-grade batch production records.

00:20:47 - CAPA Investigations: The Month-Long Delay

• Identifying root causes and implementing Corrective and Preventive Actions (CAPA) after a deviation can halt operations for a month or more.

00:24:43 - Dry Runs, Sandbox Runs, and Facility Validation

• Moving to a new facility introduces new variables, making pre-validation dry runs and expensive engineering runs crucial for uncovering operational vulnerabilities.

00:28:33 - The Ultimate Goal: Patient Safety and Regulatory Approval

• Rigorous documentation and safe processes are ultimately required to secure regulatory approval and prevent adverse events in patients.

In this episode of Out of the Lab, we sit down with patient advocate Melinda Bachini to explore the real-world operational barriers holding back access to cell and gene therapies.

Melinda shares her incredible journey from receiving a stage four terminal cholangiocarcinoma diagnosis 16 years ago to becoming a pioneer in cell therapy treatments at the National Cancer Institute (NCI). Her story, which has been featured in the Science journal and the New York Times, highlights the massive gap between scientific breakthroughs and actual patient access.

We dive deep into the heavy logistical and financial burdens placed on patients, including her own experience traveling from Billings, Montana, to Bethesda, Maryland, while arranging care for her six children.

Key topics covered in this episode:

• The immense travel and financial obstacles rural patients face when trying to access clinical trials.

• Why decentralized manufacturing could be the "next frontier" for bringing individualized cell therapies to community settings.

• The critical need to include a patient advocate's voice in clinical trial design and research from the very beginning.

• Why requiring patients to progress on a standard of care before entering an experimental trial is a major hurdle that needs to change.

• The forward-thinking concept of banking a patient's cells preventatively after surgery to prepare for potential cancer recurrence.

Melinda’s perspective is a crucial reminder for companies and researchers that medical breakthroughs only change lives if patients can actually reach them.

Show Notes:

• 00:15 - 03:02: Operational Barriers to Access

• 03:02 - 04:32: The Challenge of Manufacturing and Rural Access

• 04:32 - 06:14: Impact on Caregivers and Families

• 06:14 - 07:50: Future Frontiers in Treatment

• 07:50 - 11:47: Improving the Clinical Trial Process

• 11:47 - 13:46: Personal Experience with TIL Therapy

• 13:46 - 15:02: Evolution of Accessibility

• 15:02 - 18:43: Personal Story and Birth of Advocacy